Mechanical thrombectomy

In April 2025, the HTA body of Tuscany Regional Healthcare published six rapid HTA reports (five new assessments and one reassessment) of medical devices in the cardiovascular, peripheral vascular, endoscopy, and dermatology fields.

The French National Authority for Health (HAS) has released new recommendations regarding add-on reimbursement for medical devices and medical aids following the March 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Six favorable opinions were published concerning the registration of new devices or modifying conditions/indications for existing ones in the List of Reimbursable Products and Services (LPPR). The recommendations relate to devices in the fields of cardiovascular, peripheral vascular, endocrine, neuromodulation, and medical aids.

On January 30, 2025, the Institute for the Hospital Remuneration System (InEK) published the list of requests for innovation funding (NUB) submitted by hospitals in 2024. The medical technologies of cardiovascular, endoscopy, extracorporeal, gastrointestinal, neuromodulation, peripheral vascular, and other technology groups obtained positive status 1.

In October 2024, the updated version of the intra-DRG list was published in France. Three new devices were registered in the cardiovascular and neurovascular fields. Furthermore, one device was removed from the list, and the registration conditions for several devices were changed.

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 16951 of July 22, 2024, Tuscany Regional Healthcare published five new assessments and two reassessments of medical devices in the cardiovascular, peripheral vascular, surgical procedures, and obstetrics and gynecology areas.

In April 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects which received a subsidy under the "Subsidy scheme for promising care" in 2024 for research of targeted muscle reinnervation during leg amputation and thrombectomy by catheterization in adult patients with a high-risk pulmonary embolism.

On April 8, 2024, the updated version of the intra-DRG list of April 6, 2024, was published. One new device was registered, and other changes concerned modifying the registration conditions and renewing registration or extending the registration.

On February 08, 2024, the Austrian Institute for HTA (AIHTA) published the 2023 annual HTA report. The report contains AIHTA works, activities, and publications in 2023, including medical technologies belonging to technology groups such as robotic surgery, diagnostic imaging, and neurology.

On January 30, 2024, the Institute for the Hospital Remuneration System (InEK) published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2023. The medical technologies of cardiovascular, ENT, extracorporeal, gastrointestinal, neuromodulation, and other technology groups obtained positive status 1.

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 26990 of December 18, 2023, Tuscany Regional Healthcare has published assessments of three medical devices in the peripheral vascular, orthopedic, and dermatology areas.

In the fourth quarter of 2023, two new health technology assessments were initiated by the Agency for Health Technology Assessment and Tariff System (AOTMiT). The assessments belong to the cardiovascular and neurovascular technology groups.

In November 2023, the National Institute for Health and Care Excellence (NICE) published four new Interventional Procedure Guidance (percutaneous thrombectomy for pulmonary embolism, percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis, biodegradable subacromial spacer insertion for rotator cuff tears, extracorporeal carbon dioxide removal for acute respiratory failure) and one Health Technology Evaluation using early value assessment (virtual reality technologies for treating agoraphobia or agoraphobic avoidance). Also, five clinical guidelines were updated.